南方医科大学学报
南方醫科大學學報
남방의과대학학보
JOURNAL OF SOUTHERN MEDICAL UNIVERSITY
2009年
8期
1599-1601
,共3页
阻塞性睡眠呼吸暂停%血清淀粉样蛋白A%心血管疾病
阻塞性睡眠呼吸暫停%血清澱粉樣蛋白A%心血管疾病
조새성수면호흡잠정%혈청정분양단백A%심혈관질병
obstructive sleep apnea syndrome%serum amyloid A%cardiovascular diseases
目的 检测阻塞性睡眠呼吸暂停综合征(OSAS)患者血清淀粉样蛋白A(SAA)水平,探讨OSAS患者并发心血管疾病的机制.方法 选取经多导睡眠仪监测诊断的80例OSAS患者,分为轻度OSAS组(n=22)、中度OSAS组(n=23),重度OSAS组(n=35).选取20名健康者为正常对照组.用酶联免疫法检测各组间SAA水平并进行相关性分析.结果 轻度、中度及重度OSAS组血清SAA水平分别为(1.66±0.73)、(2.72±1.12)、(4.08±1.85)μg/ml,均高于正常对照组的(0.66±0.59)μg/ml(P<0.05).不同程度OSAS患者组间SAA水平差异具有显著性(P<0.01),且SAA水平随OSAS程度加重而增高.0SAS患者SAA水平与呼吸暂停低通气指数、夜间血氧饱和度低于90%时间呈正相关,与夜间最低血氧饱和度呈负相关.20例重度OSAS患者经3个月经鼻持续气道正压通气(nCpAP)治疗后血清SAA水平明显降低(4.13±2.27vs 5.14±2.30 μg/ml)(P<0.01).结论 OSAS患者血清SAA水平明显升高且与OSAS严重程度相关,可能是OSAS患者易患心血管疾病的原因之一.nCPAP治疗可能有助于降低OSAS患者并发心血管疾病的危险性.
目的 檢測阻塞性睡眠呼吸暫停綜閤徵(OSAS)患者血清澱粉樣蛋白A(SAA)水平,探討OSAS患者併髮心血管疾病的機製.方法 選取經多導睡眠儀鑑測診斷的80例OSAS患者,分為輕度OSAS組(n=22)、中度OSAS組(n=23),重度OSAS組(n=35).選取20名健康者為正常對照組.用酶聯免疫法檢測各組間SAA水平併進行相關性分析.結果 輕度、中度及重度OSAS組血清SAA水平分彆為(1.66±0.73)、(2.72±1.12)、(4.08±1.85)μg/ml,均高于正常對照組的(0.66±0.59)μg/ml(P<0.05).不同程度OSAS患者組間SAA水平差異具有顯著性(P<0.01),且SAA水平隨OSAS程度加重而增高.0SAS患者SAA水平與呼吸暫停低通氣指數、夜間血氧飽和度低于90%時間呈正相關,與夜間最低血氧飽和度呈負相關.20例重度OSAS患者經3箇月經鼻持續氣道正壓通氣(nCpAP)治療後血清SAA水平明顯降低(4.13±2.27vs 5.14±2.30 μg/ml)(P<0.01).結論 OSAS患者血清SAA水平明顯升高且與OSAS嚴重程度相關,可能是OSAS患者易患心血管疾病的原因之一.nCPAP治療可能有助于降低OSAS患者併髮心血管疾病的危險性.
목적 검측조새성수면호흡잠정종합정(OSAS)환자혈청정분양단백A(SAA)수평,탐토OSAS환자병발심혈관질병적궤제.방법 선취경다도수면의감측진단적80례OSAS환자,분위경도OSAS조(n=22)、중도OSAS조(n=23),중도OSAS조(n=35).선취20명건강자위정상대조조.용매련면역법검측각조간SAA수평병진행상관성분석.결과 경도、중도급중도OSAS조혈청SAA수평분별위(1.66±0.73)、(2.72±1.12)、(4.08±1.85)μg/ml,균고우정상대조조적(0.66±0.59)μg/ml(P<0.05).불동정도OSAS환자조간SAA수평차이구유현저성(P<0.01),차SAA수평수OSAS정도가중이증고.0SAS환자SAA수평여호흡잠정저통기지수、야간혈양포화도저우90%시간정정상관,여야간최저혈양포화도정부상관.20례중도OSAS환자경3개월경비지속기도정압통기(nCpAP)치료후혈청SAA수평명현강저(4.13±2.27vs 5.14±2.30 μg/ml)(P<0.01).결론 OSAS환자혈청SAA수평명현승고차여OSAS엄중정도상관,가능시OSAS환자역환심혈관질병적원인지일.nCPAP치료가능유조우강저OSAS환자병발심혈관질병적위험성.
Objective To detect the levels of serum amyloid A (SAA) and explore the pathogenesis of cardiovascular diseases in patients with obstructive sleep apnea syndrome (OSAS). Methods Polysomnography was performed in 80 patients with OSAS and 20 control subjects matched for age and body mass index. The patients with OSAS were divided into mild OSAS group (n=22), moderate OSAS group (n=23) and severe OSAS group (n=35) according to the apnea hypopnea index (AHI).Serum amyloid A levels were measured in all the subjects by enzyme-linked immunosorbent assay for correlation analysis.Results Serum amyloid A levels in mild OSAS group (1.66±0.73 μg/ml), moderate OSAS group (2.72±1.12 μg/ml) and severe OSAS group (4.08±1.85 μg/ml) were significantly higher than those in the control group (0.66±0.59 μg/ml) (P<0.05).SAA levels also differed significantly between the 3 OSAS groups (P<0.01), increasing with the severity of OSAS. Correlation analysis indicated that SAA level was positively correlated to AHI (r=0.649, P<0.01) and TSaO_2<90% 0=0.491, P<0.01), but inversely yo miniSaO_2 (r=-0.499, P<0.01). After 3 months of nCPAP therapy, SAA levels were significantly decreased in the 20 patients with severe OSAS (4.13±2.27 μg/ml vs 5.14±2.30 μg/ml, P<0.01). Conclusion SAA levels are elevated in OSAS patients in close correlation to the severity of OSAS, which may contribute to the vulnerability of the patients to cardiovascular diseases. nCPAP therapy help reduce the risk for cardiovascular diseases in OSAS patients.
